6-Year clinical results and survival of Copeland Resurfacing hemiarthroplasty of the shoulder in a consecutive series of 279 cases
Publication date: Available online 22 May 2019Source: Journal of Clinical Orthopaedics and TraumaAuthor(s): Andrew P. Dekker, Nirad Joshi, Marie Morgan, Marius Espag, Amol Tambe, David I. ClarkAbstractBackgroundMedium-term clinical results and survival of the Copeland resurfacing hemiarthroplasty of the shoulder (CRHA) in a large consecutive group are presented with a comparison of outcomes for underlying pathologies.MethodsA consecutive series of patients undergoing CRHA over 14 years was retrospectively analysed with no exclusions. Patients had a minimum 2-year follow-up by an independent assessor. Functional outcome was assessed using the Oxford Shoulder Score (OSS) and Constant-Murley Score (CMS). Pain and satisfaction was assessed using a visual analogue score.Results279 CRHAs were performed in 242 patients between 2002 and 2016. The mean follow-up was 6 years. The indication for surgery was osteoarthritis (OA) in 212, inflammatory arthropathy (RA) in 35, rotator cuff tear arthropathy (CTA) in 22 and avascular necrosis (AVN) in 2. For the OA group, 5-year survival was 90%, 10-year survival was 83% and mean survival was 13.2 years (95% CI 12.5–13.9). The mean OSS was 35.0 and mean CMS 49.9. CRHA for CTA had significantly poorer (p
Unity Biotechnology is the furthest ahead of the growing number of young biotech companies working on senolytic therapies that can selectively destroy harmful senescent cells in aged tissues. The company has already started human trials for osteoarthritis of the knee, using local rather than systemic administration of a small molecule senolytic drug. Other companies in the space, such as Oisin Biotechnologies, will be starting in on human trials for their approaches soon. As noted here, Unity Biotechnology recently announced results from their trial. The accumulation of senescent cells throughout the body over the y...
ConclusionsRobotic-assisted medial and lateral UKAs demonstrated satisfactory clinical outcomes and excellent survivorship at 3-year follow-up. Continued patient follow-up is needed to determine the long-term device performance and clinical satisfaction.Level of evidenceRetrospective cohort study, Level IV.
Journal of Orthopaedic&Sports Physical Therapy, Ahead of Print.
Clinical guidelines recommend exercise as a core treatment for individuals with knee osteoarthritis (OA). However, the best type of exercise for clinical benefits is not clear, particularly in different OA sub...
Condition: Severe Osteoarthritis of the Knee Interventions: Biological: Ampion; Other: Saline Sponsor: Ampio Pharmaceuticals. Inc. Not yet recruiting
Conclusion: The patients achieved better health benefits from manual therapy when it was combined with cryotherapy. PMID: 31202210 [PubMed - in process]
CONCLUSION: Although the first results are promising a longer follow-up with more patients is needed to draw a definite conclusion regarding the joint preserving potential in AVN. PMID: 31204506 [PubMed - as supplied by publisher]
ConclusionFasinumab provided improvements in OA pain and function, even in those benefitting little from previous analgesic. The observed “benefit to risk” relationship favors further clinical development to explore the lowest doses of fasinumab.This article is protected by copyright. All rights reserved.
ConclusionPatients with shoulder OA undergoing aTSA have higher rates of return to work, function, and satisfaction than those undergoing HHA.
ConclusionThese findings indicate that the HFS Weanling group animals were better able to cope with the dietary challenge of an HFS diet than the HFS Adult group animals. Interestingly, when assessing various serum pro-inflammatory markers, no significant differences were detected between the HFS Adult and HFS Weanling groups. Although details regarding the mechanisms underlying an increase in knee joint damage scores in the HFS Adult group remain to be elucidated, these findings indicate that dietary exposure time maybe less important than the age at which a HFS diet is introduced. Moreover, increases in serum pro-inflamm...